• Japan’s health ministry cleared Merck’s subcutaneous Keytruda QLEX for all Keytruda indications approved in Japan.
• The product, to be marketed as Keyject, can be administered in 1 minute every 3 weeks or 2 minutes every 6 weeks.
• Approval relied on Phase 3 MK-3475A-D77 data showing comparable exposure and similar response rates versus IV Keytruda in metastatic NSCLC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260921161118) on September 21, 2026, and is solely responsible for the information contained therein.